Connect with us

Cannabis

Orchid Ventures Announces Launch of New Product Lines for PurTec Delivery Systems

GlobeNewswire

Published

on

VANCOUVER, Wash., Oct. 06, 2020 (GLOBE NEWSWIRE) — ORCHID VENTURES, INC. (CSE: ORCD OTC: ORVRF) (the “Company” or “Orchid”), a multi-state cannabis innovation company, is pleased to announce that it’s hardware manufacturing subsidiary, PurTec Delivery Systems, has finalized development and testing on two new products; a disposable vape, and the most stringently tested value cartridge in the market. Both products have been through leach testing, which determines if any toxic materials or heavy metals leach into the oil put into the cart, as well as PurTec’s industry leading AFNOR standards emissions testing. An emissions test evaluates the actual vapor exiting the hardware, which is what consumers inhale.

“Our focus is to design and engineer the highest quality vaporizer products in the industry for all spectrums of the market, from value to high-end. We believe that all levels of the market should have access to safe, tested, and reliable products for their consumers, and we have made it our mission to deliver this. No longer is there a reason or excuse to purchase untested, unsafe, and unreliable hardware for the CBD and cannabis market. The newest round of products is a representation of that mission,” said Luke Hemphill, Chief Revenue Officer of Orchid Ventures. “The demand we’ve seen for emissions tested products, as well as disposable products emulating the trends we see in the nicotine industry has been fuel for our development. Our new slimline PurCore Silo we believe to be the new standard of disposable vapes. These two new product lines are now available to customers worldwide.”

ABOUT ORCHID ESSENTIALS

Orchid Essentials is an Irvine, CA-based cannabis innovation company, that launched in Oregon and California in August 2017 and has since developed a mass-market brand and loyal consumer following with its premium cannabis products and unique vape hardware delivery system. Since July 2019, Orchid has diversified its efforts and has brought to market innovative services and product offerings to support brands throughout the global cannabis industry. Orchid has diversified its portfolio to include PurTec Delivery Systems, a company that produces, markets and sells clean vaporizer hardware that has been emissions tested against the most stringent standards in the world set forth by the EU and has unrivaled product quality and value pricing. Orchid, through its wholly owned subsidiary, has launched a patented and clinically proven bioavailability solution to increase the absorption of THC and other cannabinoids making products much more effective and an activation time of less than ten minutes. With a continued focus on brand and intellectual property development, Orchid will continue to create new and innovative products and technologies, then bring them to the global cannabis marketplace and set the gold standard for delivery systems whether it’s vape or formulation sciences. Orchid’s management brings significant branding, product development and distribution experience with a proven track record of scaling businesses and building sustainable revenue growth through value-generating partnerships and innovation that creates enterprise value. Learn more at https://orchidessentials.com/

ON BEHALF OF THE BOARD OF DIRECTORS – ORCHID VENTURES, INC.

Corey Mangold
CEO and Director
investors@orchidessentials.com

Investor Relations
Corey Mangold
949-357-5818
corey@orchidessentials.com

The CSE does not accept responsibility for the adequacy or accuracy of this release. 

Safe Harbor Statement

Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.   Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Orchid Ventures, Inc. and Orchid Essentials any of its affiliates or subsidiaries (collectively, the “Company”) or its management, identify forward-looking statements.  These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s Canadian securities regulatory filings with sedar.com,   Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s Canadian securities regulatory filings with sedar.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/37ed2184-602a-47b7-b3b3-93c83ba436e5

Cannabis

Sixth Wave Continues Phase 2 Rapid COVID Test Development and Receives Funding from Nova Scotia COVID-19 Response Council

Newsfile

Published

on

Halifax, Nova Scotia–(Newsfile Corp. – October 27, 2020) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) (“Sixth Wave”, “SIXW” or the “Company”) is pleased to announce that it has received a $250,000 contribution from the Nova Scotia COVID-19 Response Council (“NSCRC”) for the development of its proposed AMIPs technology for the rapid detection of viruses such as SARS-CoV-2 (“SARS-CoV-2” or the “Virus“). AMIPs is based on Sixth Wave’s patented and patent-pending molecularly imprinted polymer systems.

Under the terms of the Agreement, dated October 22, 2020, Sixth Wave will continue to develop an Accelerated Molecularly Imprinted Polymer (the “AMIPs“) specifically for the purpose of quickly and selectively binding to the Virus. The proposed technology also contemplates the rapid delivery of a visual and/or electronic response upon the detection and verification of the Virus. The Company’s intention is to incorporate the AMIPs technology into a several rapid-detection products, including rapid virus test kits, SmartMask, as well as air and water monitoring systems. The ability to have the AMIPs detection and reporting directly integrated into devices such as Personal Protective Equipment (PPE’s) will seamlessly provide the detection and the ability to automatically disseminate results for use in outbreak tracking and contact tracing (as may be implemented by appropriate Government agencies). The development of the air monitoring technology is the subject of the Company’s previously approved and announced (June 15, 2020) collaboration with York University and Centre Technologique des Residus Industriels which has received support from the Natural Sciences and Engineering Research Council of Canada (“NSERC”).

This Project represents the first outside funding in the development of the Company’s proposed AMIPs virus detection technology, and expands the SIXW footprint in Nova Scotia. As previously announced (May 15, 2020), SIXW has already engaged Neocon International Inc., a premier manufacturing company in Dartmouth to commercialize the SmartMask product. Moreover, SIXW has executed a Memorandum of Understanding with Dalhousie University to explore near term opportunities to establishing a research and development presence in the Province.

“Our sincere appreciation to the Province of Nova Scotia for its participation in this project,” said Dr. Jon Gluckman, CEO of Sixth Wave. “Sixth Wave has a substantial history of delivering similarly complex MIP based solutions within limited timelines, as evidenced by our explosives detection wipes and bacterial pathogen diagnostic tools. We welcome this opportunity to once again prove the utility of molecular imprinting as a detection and diagnostic tool, especially in circumstances of such importance to public health and security.”

“MIP technology is well documented in the scientific literature as being a comparatively fast and reliable diagnostic tool,” said Garrett Kraft Ph.D., head of the Sixth Wave project. “MIP-based analytical technologies are also known for their flexibility, durability and accuracy. Polymer substrates demonstrate resilience under adverse conditions, and do not require climate-controlled storage as many antibody based tests do. They can therefore be readily applied to a host of materials, fabrics and other test media. These attributes along with low cost and production scalability have the potential to set AMIPs™ apart from traditional PCR and immunoassay tests.”

The company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time. AMIPs tests produced for personal use or point of care use will be subject to regulatory approval.

Project Background

The Project has a number of objectives, culminating in the development of a Molecularly Imprinted Polymer (“MIP“) formulation with measurable binding of inactivated SARS-CoV-2 in a buffer solution with limits of detection less than 15,000 virus particles / mL (comparable to several other commercially available diagnostic technologies) and a basic colorimetric response using protein labeling chemistry. Clinically relevant viral loads have been determined to be approximately 15,000 virus particles / mL. Although a MIP for the detection of SARS-CoV-2 has not previously been developed, other virus imprinted polymers have demonstrated detection limits as low as 105 virus particles / mL.

Overall, the Company’s objectives for the COVID-selective AMIPs include:

  1. Flexibility – The ability to analyze a significant variety of field samples such as specimens garnered from bodily fluids, breath, air, waste streams, and contact surfaces;
  2. Speed – The ability to detect and to communicate an electronic or visual signal almost immediately upon positive diagnosis;
  3. Ease Of Use – The ability to integrate with a variety of devices not requiring specialized training, and
  4. Low Cost – enabling widespread and frequent testing that will allow for safe return to daily activities and outbreak management.

The Company’s COVID-19 Project represents the first step in the development of a flexible platform which can be adapted to detect virtually any virus. For more information on the proposed AMIPs technology and associated fundamental and device-related patent applications, see: www.amips.com.The overall budget for this Project totals $770,000, of which $250,000 will be funded through the contribution by the NSCRC.

The Company’s molecularly imprinted polymer technology is also being commercialized in the mining and cannabis sectors.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of commercial roll out of its Affinity cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPS) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our web site at: www.sixthwave.com

ON BEHALF OF THE BOARD OF DIRECTORS

Jonathan Gluckman
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed “forward-looking statements” including statements regarding the planned use of proceeds and performance of the AMIPs technologies. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs technology are subject the risk that the AMIPs technology may not prove to be successful in detecting virus targets effectively or at all, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66918

Continue Reading

Cannabis

Curtis Mathes to Present a Live Webinar for Cannabis Science & Technology

Vlad Poptamas

Published

on

 

The Curtis Mathes Corporation (OTC: TLED) will be presenting a live webinar on November 3rd in collaboration with the peer-reviewed technical journal, Cannabis Science & Technology. The presentation, entitled “Environmental and Genetic Factors that affect the quality of Cannabis and Hemp”, will be delivered by Dr. Zacariah Hildenbrand along with a live Q&A session.

“We are thrilled to share this educational webcast with our audience as well as the knowledge and thought-leadership from one of our esteemed editorial advisory board members, Dr. Zacariah Hildenbrand,” said Meg L’Heureux, Editor-in-Chief of Cannabis Science & Technology.

“It is always a tremendous honor to disseminate new information regarding the interplay between plants and the environment,” remarked Zacariah Hildenbrand, Curtis Mathes Director and Chief Scientific Officer, “This webinar hosted by Cannabis Science & Technology is an excellent opportunity for us to discuss our latest lighting technologies and ongoing research efforts.”

“Science and research are entrenched in our DNA at Curtis Mathes,” said Robert Manes, President & COO of Curtis Mathes, “Webinars like this allow us to connect with potential collaborators while educating prospective clients on the science of horticultural lighting.”

Continue Reading

Cannabis

Medical Marijuana, Inc. and Subsidiary Kannaway® Honored in 12th Annual 2020 Golden Bridge Business and Innovation Awards

GlobeNewswire

Published

on

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) — via NewMediaWireMedical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company and its subsidiary Kannaway® have received three prestigious awards from the 12th Annual 2020 Golden Bridge Business and Innovation Awards.

The Company and its subsidiary were recognized for the following:

  • Medical Marijuana, Inc. CEO Dr. Stuart Titus: Gold Award – Lifetime Achievement Award
  • Kannaway® CEO Blake Schroeder: Gold Award – Maverick of the Year
  • Kannaway® Chief Marketing Officer Stephen Jones: Bronze Award – Marketing Executive of the Year

“Helping lead Medical Marijuana, Inc. as a pioneer in the CBD industry has been my passion for more than a decade and I am honored to receive this lifetime achievement award,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Our mission does not stop here and we will push forward as CBD continues to gain legitimacy and recognition for the potential benefits it can bring.”

The coveted annual Golden Bridge Awards program recognizes and honors the world’s best in organizational performance, products and services, innovations, executives and management teams, women in business and the professions, case studies and successful deployments, product management, websites, blogs, whitepapers, creativity, partner programs, and customer satisfaction programs from every major industry in the world.

“2020 was another eventful year for Kannaway as we continue to enter into new global markets and surpass milestones,” said Kannaway® CEO Blake Schroeder. “In 2021, we plan to continue setting new industry standards and expanding access to CBD around the globe.”

Details about the 12th Annual 2020 Golden Bridge Business and Innovation Awards and the list of 2020 winners are available at https://goldenbridgeawards.com/winners/2020-business-awards-winners/

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

About the Golden Bridge Awards

The coveted annual Golden Bridge Awards program recognizes and honors the world’s best in organizational performance, products and services, innovations, executives and management teams, women in business and the professions, case studies and successful deployments, public relations and marketing campaigns, product management, websites, blogs, white-papers, videos, advertisements, creativity, partner programs, and customer satisfaction programs from every major industry in the world. Learn more about the Golden Bridge Awards at https://goldenbridgeawards.com.

About the SVUS Awards

SVUS Awards are conferred in eleven programs: the CEO World Awards®, the Consumer World Awards®, The Customer Sales & Service World Awards®, The Globee® Awards, the Golden Bridge Awards®, the Info Security Products Guide’s Global Excellence Awards® and Security World Awards, the Network Products Guide’s IT World Awards®, One Planet® American + World Business Awards, the Pillar World Awards®, the PR World Awards® for Public Relations and Communications, and the Women World Awards®. Honoring organizations of all types and sizes and the people behind them, the SVUS Awards recognize outstanding achievements and performances in businesses worldwide. Learn more about the SVUS Awards at https://svusawards.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:
Public Relations Contact:

Kathryn Reinhardt

Account Supervisor

CMW Media

P. 858-264-6600

kathryn@cmwmedia.com

www.cmwmedia.com

Investor Relations Contact:

P. (858) 283-4016

Investors@medicalmarijuanainc.com

Attachment

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania